BioGaia L. reuteri effective in the prevention of infantile colic This randomised, controlled, single-blinded, multi-centre study was performed to evaluate the efficacy of L. reuteri DSM 17938 in reducing parental discomfort due to infantile colic in a population of otherwise healthy infants. 105 infants aged less than 10 days were randomly assigned to receive five drops per day (10^8 CFU) of L. reuteri with vitamin D (n=51), or vitamin D only (n=54), for three months. Primary endpoint was measured as use of pain relieving agents. Secondary endpoints was measured as percentage of infants that switched from an exclusive breastfeeding to partial or exclusive formula feeding and number of calls to the paediatricians and number of visits at paediatricians’ ambulatories due to infantile colic The results showed: Significantly less use of pain relieving agents in infants supplemented with L. reuteri compared to control group • 75% less use of simethicone • 96% less use of cimetropium bromide This study adds evidence to the previous study with L. reuteri and the beneficial effects in the prevention of infantile colic Reference Savino F, Ceratto S, Poggi E, Cartosio ME, Cordero di Montezemolo L, Giannattasio A. Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. Beneficial Microbes. 2015 Jan 1;6(3):245-51. doi: 10.3920/BM2014.0090.
Copyright © 2022 PharmaAce. All Rights Reserved.
|
 |